A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans

Authors

Mikko Holtta, University of Gothenburg,
Robert A. Dean, Eli Lilly and Company
Eric Siemers, Eli Lilly and Company
Kwasi G. Mawuenyega, Washington University School of Medicine in St. Louis
Wendy Sigurdson, Washington University School of Medicine in St. Louis
Patrick C. May, Eli Lilly and Company
David M. Holtzman, Washington University School of Medicine in St. Louis
Erik Portelius, University of Gothenburg
Henrik Zetterberg, University of Gothenburg
Randall J. Bateman, Washington University School of Medicine in St. Louis
Kaj Blennow, University of Gothenburg
Johan Gobom, University of Gothenburg

Journal

Alzheimer's Research & Therapy

Publication Date

2016

Volume

8

Inclusive Pages

11

Document Type

Open Access Publication

DOI

10.1186/s13195-016-0178-x

Rights and Permissions

Hölttä et al. Alzheimer's Research & Therapy (2016) 8:11 DOI 10.1186/s13195-016-0178-x

Recommended Citation

Holtta, Mikko; Dean, Robert A.; Siemers, Eric; Mawuenyega, Kwasi G.; Sigurdson, Wendy; May, Patrick C.; Holtzman, David M.; Portelius, Erik; Zetterberg, Henrik; Bateman, Randall J.; Blennow, Kaj; and Gobom, Johan, "A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans." Alzheimer's Research & Therapy. 8, 11. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/4627